Two small trials, two large questions: can food compounds and cheap antidepressants ease the lingering burden of age and long COVID?

A 50-milligram capsule of spermidine, taken daily for three months, was enough to push antibody responses to a standard flu vaccine measurably higher in a group of adults over 60, according to a small pilot trial reported on 21 July 2026. The compound, abundant in wheat germ, mushrooms and aged cheese, has long sat on the periphery of nutritional science. The new data suggest it deserves a closer look as a cheap, food-derived adjuvant at a moment when vaccine uptake among older adults is stuttering in much of the developed world.

The story is part of a wider pattern in late-2026 biomedical research: a slow, deliberate re-examination of familiar molecules, vitamins, metabolites, old generics, for jobs they were never designed to do. Spermidine for immune function. Fluvoxamine, the 1980s antidepressant, for long COVID fatigue. Both are early signals. Both are also reminders that the cheapest interventions often receive the least rigorous testing, and that the gap between a plausible mechanism and a clinical recommendation remains stubbornly wide.

Spermidine and the immune ceiling

The pilot trial enrolled a small cohort of older adults and randomised them to either spermidine supplementation or placebo ahead of seasonal influenza vaccination. According to the reporting, antibody titres in the supplemented arm climbed higher than in the control arm at the standard post-vaccination read-out, with the effect most visible in participants at the older end of the cohort. The exact participant count was not disclosed in the available summary.

The biology is straightforward enough to explain why the finding is plausible. Spermidine is a polyamine, a class of small molecules involved in autophagy, the cellular recycling process that clears out damaged proteins and organelles. Autophagy efficiency declines with age, and so does the naive T-cell repertoire that vaccines need to recruit. If a dietary compound can nudge autophagy back toward a more youthful profile, the immune system may, in theory, have more raw material to work with when confronted by a new antigen. The pilot does not prove that is what is happening in humans, but it is the kind of result that justifies a larger, better-powered trial with clinical endpoints rather than antibody titres alone.

The immediate stakes are practical. Seasonal influenza continues to kill tens of thousands of older adults in any given year across the OECD. If a cheap food-derived supplement could meaningfully narrow the gap between an 80-year-old's antibody response and a 40-year-old's, the public-health maths shifts. The cheaper intervention also travels better: a capsule that costs cents a day can be distributed through pharmacy networks that already exist, rather than waiting for a reformulated vaccine.

Fluvoxamine, repurposed

The second finding, dated 19 July 2026, is the more uncomfortable one for a research establishment that has spent five years arguing about long COVID. A randomised clinical trial of 399 adults found that fluvoxamine, a generic SSRI antidepressant first approved in 1994, significantly reduced fatigue and improved function in long COVID patients compared with placebo.

Fluvoxamine is not new. It is not expensive. It is off-patent almost everywhere, and a month's supply costs less than a takeaway dinner in most high-income markets. It is also not a miracle. The trial measured fatigue and functional capacity, not viral clearance or a return to baseline health, and 399 participants is a respectable but not definitive cohort. Long COVID trials have a track record of producing early signals that fail to replicate at scale.

What makes the result worth taking seriously is not its size but its direction. The trial is the latest in a string of studies pointing toward the sigma-1 receptor, the molecular target fluvoxamine binds outside its SSRI action, as a plausible lever in post-viral syndromes. The hypothesis is that sigma-1 agonism moderates the cytokine and platelet dysregulation that some researchers believe underlies the fatigue and post-exertional malaise reported by long COVID patients. That mechanism remains contested. But it has now produced enough small positive trials to warrant the kind of large, pragmatic study that regulators and guideline bodies actually trust.

Why these two stories share a structure

Neither spermidine nor fluvoxamine was developed for the role it is being asked to play. Both are old molecules, in some cases half a century old, being re-purposed for conditions that did not exist or were not recognised when they first entered the clinic. That pattern is increasingly common in 2026, partly because the cost of bringing an entirely new chemical entity to market has roughly doubled in the past decade, partly because the low-hanging therapeutic fruit in oncology and rare disease has largely been picked, and partly because large payers are now willing to fund trials of cheap generics for chronic indications that blockbusters would never target.

The structural problem this creates is one of incentives. A trial that proves wheat-germ extract improves flu vaccine titres is not a commercial event. No company owns spermidine. No patent can be obtained on the molecule itself, only on a specific formulation or dosing regimen, and even those are hard to defend. The same is true, with more force, of fluvoxamine: it is a generic that sells for cents per pill in much of the world. The trials that produced these findings were therefore funded by academic medical centres and public research councils, with no commercial sponsor racing to claim the result. The upside is methodological independence; the downside is the chronic under-funding that makes large confirmatory studies slow to organise.

Stakes, and what to watch

For older adults, the practical question is whether a clinician in 2027 will be willing to recommend a spermidine supplement alongside seasonal flu vaccination on the strength of a single pilot trial. The honest answer is no, not yet. The data need to be replicated at scale, ideally with clinical endpoints such as laboratory-confirmed influenza or hospitalisation, before any guideline body signs off. The same caution applies to fluvoxamine for long COVID: positive pilot data have a poor survival rate through phase 3, and long COVID is a heterogeneous syndrome in which a treatment that helps one subgroup may do nothing for another.

The forward calendar is therefore the story to watch. Phase 2 trials of spermidine adjuvants are reportedly being planned in at least two European cohorts. The fluvoxamine long-COVID programme is expected to feed into a larger US-based pragmatic trial within the next 12 months. If either of those studies reads out positive, the conversation shifts from mechanism to implementation, and the question becomes not whether the molecule works but who pays for it and how it reaches the patients most likely to benefit.

For now, both findings are best read as permission to keep looking, not as a reason to change clinical practice.

This desk framed both stories as pilot-stage evidence within a broader pattern of generic and food-derived compounds being re-purposed for chronic and age-related indications. The wire framing has tended to lean on the therapeutic promise; Monexus keeps the methodological caveats in view.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• https://t.me/c/2262720995/1234
• https://t.me/c/2262720995/1187
• https://en.wikipedia.org/wiki/Spermidine
• https://en.wikipedia.org/wiki/Fluvoxamine